JP6431523B2 - 抗ホスホリパーゼｄ４抗体を含む医薬 - Google Patents

抗ホスホリパーゼｄ４抗体を含む医薬 Download PDF

Info

Publication number
JP6431523B2
JP6431523B2 JP2016503264A JP2016503264A JP6431523B2 JP 6431523 B2 JP6431523 B2 JP 6431523B2 JP 2016503264 A JP2016503264 A JP 2016503264A JP 2016503264 A JP2016503264 A JP 2016503264A JP 6431523 B2 JP6431523 B2 JP 6431523B2
Authority
JP
Japan
Prior art keywords
seq
sequence
variable region
antibody
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534022A5 (enExample
JP2016534022A (ja
Inventor
智英 山崎
智英 山崎
まゆき 遠藤
まゆき 遠藤
晃司 石田
晃司 石田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of JP2016534022A publication Critical patent/JP2016534022A/ja
Publication of JP2016534022A5 publication Critical patent/JP2016534022A5/ja
Application granted granted Critical
Publication of JP6431523B2 publication Critical patent/JP6431523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016503264A 2013-07-30 2014-07-30 抗ホスホリパーゼｄ４抗体を含む医薬 Active JP6431523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013158258 2013-07-30
JP2013158258 2013-07-30
PCT/JP2014/070661 WO2015016386A1 (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018206702A Division JP2019014759A (ja) 2013-07-30 2018-11-01 抗ホスホリパーゼｄ４抗体を含む医薬

Publications (3)

Publication Number Publication Date
JP2016534022A JP2016534022A (ja) 2016-11-04
JP2016534022A5 JP2016534022A5 (enExample) 2017-09-07
JP6431523B2 true JP6431523B2 (ja) 2018-11-28

Family

ID=51493000

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503264A Active JP6431523B2 (ja) 2013-07-30 2014-07-30 抗ホスホリパーゼｄ４抗体を含む医薬
JP2018206702A Ceased JP2019014759A (ja) 2013-07-30 2018-11-01 抗ホスホリパーゼｄ４抗体を含む医薬
JP2019173621A Active JP6843449B2 (ja) 2013-07-30 2019-09-25 抗ホスホリパーゼｄ４抗体を含む医薬

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018206702A Ceased JP2019014759A (ja) 2013-07-30 2018-11-01 抗ホスホリパーゼｄ４抗体を含む医薬
JP2019173621A Active JP6843449B2 (ja) 2013-07-30 2019-09-25 抗ホスホリパーゼｄ４抗体を含む医薬

Country Status (17)

Country Link
US (2) US20160168266A1 (enExample)
EP (1) EP3027656B1 (enExample)
JP (3) JP6431523B2 (enExample)
KR (1) KR102367760B1 (enExample)
CN (1) CN105745226B (enExample)
AU (1) AU2014297217B2 (enExample)
BR (1) BR112016002001B1 (enExample)
CA (1) CA2919736C (enExample)
DK (1) DK3027656T3 (enExample)
ES (1) ES2736324T3 (enExample)
HU (1) HUE044469T2 (enExample)
MX (1) MX381725B (enExample)
PL (1) PL3027656T3 (enExample)
RU (1) RU2709741C2 (enExample)
SG (2) SG11201600666SA (enExample)
TR (1) TR201910330T4 (enExample)
WO (1) WO2015016386A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
SG11201600666SA (en) * 2013-07-30 2016-02-26 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型ｔｌｒ７の分析

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139900T1 (de) * 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
EP1392855A4 (en) * 2000-12-07 2005-05-25 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF VIRAL DISEASES VIA GENE 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
SG11201600666SA (en) * 2013-07-30 2016-02-26 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody

Also Published As

Publication number Publication date
JP6843449B2 (ja) 2021-03-17
JP2019014759A (ja) 2019-01-31
BR112016002001B1 (pt) 2023-04-25
DK3027656T3 (da) 2019-08-05
CA2919736C (en) 2022-03-22
JP2016534022A (ja) 2016-11-04
CN105745226B (zh) 2020-03-06
HUE044469T2 (hu) 2019-10-28
RU2709741C2 (ru) 2019-12-19
RU2016106708A3 (enExample) 2018-03-30
PL3027656T3 (pl) 2019-10-31
US20160168266A1 (en) 2016-06-16
ES2736324T3 (es) 2019-12-27
RU2016106708A (ru) 2017-09-01
KR102367760B1 (ko) 2022-02-24
AU2014297217B2 (en) 2020-01-16
KR20160034934A (ko) 2016-03-30
SG11201600666SA (en) 2016-02-26
JP2019214621A (ja) 2019-12-19
BR112016002001A2 (pt) 2017-08-29
TR201910330T4 (tr) 2019-07-22
EP3027656B1 (en) 2019-06-26
EP3027656A1 (en) 2016-06-08
SG10201800592SA (en) 2018-03-28
US20210130493A1 (en) 2021-05-06
MX381725B (es) 2025-03-13
MX2016001193A (es) 2016-05-26
CA2919736A1 (en) 2015-02-05
CN105745226A (zh) 2016-07-06
AU2014297217A1 (en) 2016-02-18
WO2015016386A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
JP6843449B2 (ja) 抗ホスホリパーゼｄ４抗体を含む医薬
JP7244102B2 (ja) 抗ホスホリパーゼｄ４抗体
JP6412072B2 (ja) 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体
JP2019531284A (ja) Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
WO2022228445A1 (en) Single domain pd-l1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160125

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181102

R150 Certificate of patent or registration of utility model

Ref document number: 6431523

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250